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Introduction
Ayurveda, the Indian traditional system of medicine, which
dates back many centuries, uses many herbal extracts to cure
a variety of diseases including cancer. One such popularly
used plant that is reported to have antitumor, radiosensitizer,
antistressor, immunomodulatory, anti-inflammatory and anti-
bacterial effects is Withania somnifera Dunal, which is com-
monly known as ‘Ashwagandha’ (1–5).  Withania holds a
position of importance similar to ginseng in China, having
also a rejuvenativing effect on the body; however, this plant is
little known in the West. Withania somnifera belongs to the
family  Solanaceae, and is an evergreen tomentose shrub,
grown wild and also cultivated for medicinal use in many parts
of India. The roots of W.somnifera contain several alkaloids,
withanolides, a few flavanoids and reducing sugars (5,6). The
active compounds reported in W.somnifera include withaferin
A, sitoindosides VII–X, 5-dehydroxywithanolide-R, withasom-
niferin-A, 1-oxo-5 ,6 -epoxy-witha-2-ene-27-ethoxy-olide,
4-(1-hydroxy-2,2-dimethylcyclpropanone)-2,3-dihydrowithaferin
A, 2,3-dihydrowithaferin A, 24,25-dihydro-27-desoxywithaferin
A, physagulin D (1→6)- -D-glucopyranosyl-(1→4)- -
D-glucopyranoside, 27-O- -D-glucopyranosylphysagulin D,
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We evaluated the cancer chemopreventive efficacy of the Withania somnifera root, which has been used
in the Indian traditional medicine system for many centuries for the treatment of various ailments. Since,
studies showing its mechanism-based cancer chemopreventive efficacy are limited, this was investigated
in the present study. We studied the effect of dietary administration of Withania root on hepatic phase I,
phase II and antioxidant enzymes by estimation of its level/activity, as well as in attenuating carcino-
gen-induced forestomach and skin tumorigenesis in the Swiss albino mouse model. Our findings
showed that roots of W.somnifera inhibit phase I, and activates phase II and antioxidant enzymes in the
liver. Further, in a long-term tumorigenesis study, Withania inhibited benzo(a)pyrene-induced forestom-
ach papillomagenesis, showing up to 60 and 92% inhibition in tumor incidence and multiplicity, respec-
tively. Similarly, Withania inhibited 7,12-dimethylbenzanthracene-induced skin papillomagenesis,
showing up to 45 and 71% inhibition in tumor incidence and multiplicity. In both studies, Withania
showed no apparent toxic effects in mice as monitored by the body weight gain profile. Together, these
findings suggest that W.somnifera root has chemopreventive efficacy against forestomach and skin car-
cinogenesis and warrants the identification and isolation of active compounds responsible for its anti-
cancer effects, which may provide the lead for the development of antitumor agents.
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lviscosalactone B, 4,16-dihydroxy-5 ,6 -epoxyphysagulin D,
viscosalactone B and diacetylwithaferin A (5–9). These reports
suggest that Withania is a rich source of bioactive compounds.
The overall metabolism of exogenous xenobiotic com-
pounds is directed towards producing chemical species that
can be excreted from the body. Two classes of enzyme systems
have been shown for the metabolism of xenobiotic com-
pounds. They are phase I and phase II enzymes. The microso-
mal cytochrome P450 system that is a product of the CYP
superfamily of genes constitutes a major electron transport
chain in the endoplasmic reticulum of mammalian cells. It
plays a pivotal role in oxidative activation of several toxic
xenobiotic compounds, including carcinogens, followed by
their detoxification by phase II enzymes and subsequent excre-
tion (10). Carcinogen-induced skin and forestomach papillo-
magenesis in animal models have been widely used to study
the chemopreventive potential of various agents. The 7,12-
dimethylbenzanthracene (DMBA)–12-O-tetradecanoylphorbol-
13-acetate (TPA) model of skin carcinogenesis involves initiation,
promotion and progression, and provides ample scope for
studying the stage-specific effect of a chemopreventive com-
pound (11). Several phytochemicals have been tested in this
model, and found to have substantial potential to prevent cancer
(11,12). Forestomach papillomagenesis is initiated by benzopy-
rene and involves an endogenous promoter for tumor growth
and progression (13). There are few studies showing the anti-
cancer potential of Withania in the mouse skin carcinogenesis
model (14,15). To the best of our knowledge, this is the first
study reporting the chemopreventive efficacy of Withania root in
carcinogen-induced forestomach papillomagenesis in a mouse
model. There are two studies reporting the chemopreventive
potential of Withania against skin carcinogenesis; one study
used oral administration (14), while the other used intraperi-
toneal injection of Withania root extract (15); however, in the
present study, we used dietary administration of Withania root.
Dietary administration of the test agent is the preferred method
in the study of cancer chemoprevention, as it is practical for pre-
ventive measures and provides better absorption and physiolog-
ical distribution of the test agent (16). Moreover, our findings in
forestomach carcinogenesis are novel, whereas in skin carcino-
genesis support earlier findings but with a different form and
mode of administration of Withania than those reported earlier.
Methods
Mice
Swiss albino mice (6 weeks old) used for this study were
maintained in the animal house facility of Jawaharlal Nehru
University, New Delhi with controlled temperature and a 12 h
light/dark cycle. Animal handling and care were in accord with
NIH guidelines. Mice were provided with standard food
pellets (Hindustan Lever Ltd, India) and regular drinking water
ad libitum. Standard rodent diet was composed of (w/w) wheat
(60.3%), roasted bengal gram (28.2%), refined peanut oil
(5%), skimmed milk powder (1%), casein (1%), vitamin mix-
ture (0.5%) and mineral mixture (4%), as recommended by
the National Institute of Nutrition, Hyderabad, India. In skin
tumor studies, the hairs on the back of mice were clipped
before the first treatment and thereafter were shaved when
needed during the experiment.
Plant Material and Preparation of Test Diet
The dried roots of W.somnifera were purchased from an
authorized dealer in New Delhi, India, and were authenticated
by a competent botanist, Dr Raveesha, at the Department of
Botany, Mysore University, Mysore, India, and a voucher
specimen was preserved in our laboratory (Fig. 1). The major
active compounds in roots are reported to be withanolides,
glycosides and many different alkaloids. To date, up to 19
withanolide derivatives have been isolated from Withania
roots (17). The roots were thoroughly washed with 95% ethanol
and with sterile water, and air-dried and powdered. Next, 125 g
(2.5%, w/w) and 250 g (5%, w/w) of the powdered root were
mixed uniformly with 5 kg of standard laboratory diet each
and made into pellets. Mice were subjected to control diet and
these experimental diets during the experiment as mentioned.
We observed that 2 weeks of dietary feeding of Withania at
these doses did not show any loss in body weight or reduction
in diet consumption in mice; therefore, the same test diets were
used for the study of tumorigenesis.
Study of Xenobiotic Metabolizing Enzymes in Liver
For the study of xenobiotic metabolizing enzymes in liver,
mice were divided into three groups (six mice/group): group I,
control group; group II, low dose; and group III, high dose,
with 0, 2.5 and 5% (w/w) of Withania in the diet, respectively,
and fed for 14 days. Mice were sacrificed by cervical
dislocation and the entire liver was then perfused immedi-
ately with ice-cold 0.9% normal saline and thereafter carefully
removed, trimmed free of extraneous tissue and rinsed in
chilled 0.15 M Tris–KCl buffer (pH 7.4). The liver was then
blotted dry, weighed quickly and homogenized in ice-cold
0.15 M Tris–KCl buffer (pH 7.4) to yield a 10% (w/v)
homogenate. An aliquot of this homogenate (0.5 ml) was used
for assaying the acid-soluble sulfhydryl group (-SH) as
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Figure 1. Roots of Withania somnifera.published recently (18). The remainder of the homogenate was
processed for microsome and cytosolic fractions (18). The
microsome fraction was used for the estimation of cytochrome
P450 (cyt P450) and cytochrome b5 enzymes (cyt b5).
The cytosolic fraction was used for assaying total cytosolic
glutathione  S-transferase (GST), DT-diaphorase (DTD),
superoxide dismutase (SOD), catalase (CAT) and lactate
dehydrogenase (LDH) activities.
Assays for Cytochrome P450 and Cytochrome b5
Cyt P450 was determined by using the carbon monoxide
difference spectra. Both cyt P450 and cyt b5 contents were
assayed in the microsomal suspension by the method of
Omura and Sato (19), using absorption coefficients of 91 and
185 cm2/mmol, respectively, as reported earlier (20).
Assays for GST, DTD, SOD, CAT and LDH 
Enzyme Activities
The cytosolic GST activity was determined according to the
standard procedure of Habig et al. (21). The specific activity of
GST is expressed as  mol of GSH–CDNB conjugate formed/
min/mg protein using an extinction coefficient of 9.6/mM/cm.
DTD activity was measured by following the procedure of
Ernster  et al. (22) with nicotinamide adenine dinucleotide
(NADH) as the electron donor and 2,6-dichlorophenol-
indophenol (DCPIP) as the electron acceptor, at 600 nm. The
activity was calculated using an extinction coefficient of
21/mM/cm. One unit of enzyme activity was defined as the
amount of enzyme required to reduce 1  mol of DCPIP/min.
SOD was assayed by the method of Marklund and Marklund
(23), which involves inhibition of pyrogallol autoxidation at
pH 8.0, as reported earlier (20,24). A single unit of enzyme
activity is defined as the quantity of SOD required to produce
50% inhibition of autoxidation. CAT activity was monitored
by the decomposition of H2O2 as reported recently (20,24).
The specific activity of catalase has been expressed as mol
of H2O2 reduced/min/mg of protein. LDH was assayed by
measuring the rate of oxidation of NADH at 340 nm according
to the method of Bergmeyer and Bernt as reported recently
(20,24). The enzyme activity was calculated using an extinc-
tion coefficient of 6.22/mM/cm. One unit of enzyme activity
is defined as that causing oxidation of 1  mol of NADH/min.
Protein was estimated by the Lowry method as reported
earlier (20,24).
Assays for B(a)P-induced Forestomach Papillomagenesis
The effect of Withania diets on benzo(a)pyrene [B(a)P]-
induced forestomach tumors was studied as described by
Wattenberg et al. (13) and modified by Azuine and Bhide (25).
Female Swiss albino mice (6 weeks old) were kept on 2.5 and
5% test diets and normal diet for 2 weeks (n   15–20/group).
From the third week onwards, the mice received B(a)P (1 mg
in 0.1 ml peanut oil/mouse) twice a week for 4 weeks by oral
gavage. Test/normal diets were continued during as well as
2 weeks after the carcinogen treatment. The experimental
groups were: group I, mice kept on the normal diet and who
received only B(a)P treatment twice a week for 4 weeks; group
II, mice kept on the 2.5% test diet for 2 weeks before, during
and 2 weeks after B(a)P treatment; and group III, mice fed
with the 5% test diet 2 weeks before, during and 2 weeks after
the carcinogen treatment. The body weights of the mice were
noted at regular intervals and the mice were sacrificed at the
end of 180 days. The forestomach was cut open longitudinally
and the number of papillomas was counted under a dissecting
microscope.
Analysis of DMBA-induced Skin Papillomagenesis
The effect of 2.5 and 5% Withania in the diet was evaluated on
DMBA-induced skin tumorigenesis in female Swiss albino
mice as described by Yasukawa et al. (26) with some modifi-
cations. The control group, i.e. group I (control diet), received
a single topical application of 50  g of DMBA in 50  l of
acetone per mouse on the dorsal skin. Group II (2.5% test diet)
and group III (5% test diet) also received a single topical
application of 50  g of DMBA in 50  l of acetone per animal.
Mice in groups II (LD) and III (HD) were kept on the test diets
for 2 weeks before and 2 weeks after carcinogen administra-
tion. Croton oil twice/week (0.2 ml/mouse) was used as a skin
tumor promoter in all the three groups, the treatment of which
continued until the end of the experiment (12 weeks after
DMBA treatment). Each group comprised 15 mice.
Histopathology of Tumor Samples
Tissue samples collected from both the forestomach and skin
tumorigenesis study were processed conventionally using
paraffin-embedded sections. These sections were deparaffinized
in xylene and rehydrated in descending concentrations of
ethanol, and stained with hematoxylin and eosin. Sections were
then dehydrated in ascending concentrations of ethanol followed
by xylene and mounted for microscopic observation.
Statistical Analysis
Statistical analysis was performed using analysis of variance
(ANOVA) following the Mann–Whitney U-test to determine
the statistical difference in the enzyme studies. Student’s t-test
was used to compare the tumor burden between control and
treated groups. P   0.05 was considered significant.
Results
Withania Modulates the Activities of Xenobiotic
Metabolizing and Antioxidant Enzymes in 
Mouse Liver
The effect of 2 weeks of dietary feeding of Withania roots was
evaluated on the activities of the cyt P450 system and antioxi-
dant enzymes in mouse liver. There was a moderate reduction
in the activity of the cyt P450 monoxygenase system. Both cyt
P450 and cyt b5 showed a slight but significant reduction
eCAM 2005;2(1) 101(13%, P   0.05; and 14%, P   0.005, respectively) in only
the LD group compared with controls (Fig. 2). Further, a sig-
nificant dose-dependent increase in the activity of the phase II
enzymes, GST (1.26-fold, P   0.001 in LD; and 1.33-fold,
P   0.01 in HD) and DTD (1.67-fold, P   0.005 in LD; and
1.98-fold, P   0.005 in HD) was observed compared with
controls (Fig. 2). Antioxidant enzymes, SOD (1.48-fold,
P   0.01 in LD; and 1.73-fold, P   0.01 in HD), and catalase
(3.15 fold, P   0.01 in LD; and 2.99 fold, P   0.01 in HD)
also showed a significant increase in the Withania root-fed
groups compared with the controls (Fig. 3). A significant
increase in GSH content was observed in the LD group (1.31-
fold, P   0.05). In the case of LDH, the activity was reduced
by 25–32% (P   0.01) in the Withania root-fed-groups, indi-
cating no cell damage/toxicity due to the treatment (Fig. 3).
Overall, these findings suggested that Withania roots increase
phase II enzyme activity as well as cellular antioxidant poten-
tial in mouse liver, which could be helpful in detoxification of
xenobiotic compounds including carcinogens.
Withania Inhibits Carcinogen-induced Forestomach
Papillomagenesis in Mice
During forestomach papillomagenesis, we observed that
dietary feeding of Withania root did not produce any decease
in body weight gain (Fig. 4A) or diet consumption. The con-
trol group treated with B(a)P alone showed a 100% incidence
of forestomach papillomas (% of mice bearing tumors) at the
end of 180 days (Fig. 4B). Estimation of the number of papil-
lomas showed 11.1   2.68 papillomas/animal in the control
group (Fig. 4C). The mice fed with the 2.5% Withania diet for
6 weeks [2 weeks before, 4 weeks during and 2 weeks after
B(a)P treatment] showed only 40% tumor incidence (Fig. 4B),
and a strong and significant (P   0.001) decrease in mean
number of papillomas/animal, which was only 0.89   1.08
(Fig. 4C). Though the tumor incidence was 87% in the HD
group, the mean number of papillomas/animal was signific-
antly (P   0.001) reduced to only 2.61   1.72 (Fig. 4C). We
also observed a slight increase in the body weight of the 
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Figure 2. Effect of the roots of Withania on hepatic phase I and phase II
xenobiotic metabolizing enzymes. Mice were exposed to control and test
diets for 14 days, and enzyme activity assays were performed as described
in Methods. Data are presented as mean   SD. Error bars represent the SD.
Co, control; LD, 2.5% Withania in the diet; HD, 5% Withania in the diet.
a( P   0.05), b (P   0.01) and c (P   0.005) indicate significant changes
compared with control.
Figure 3. Roots of Withania induce hepatic reduced glutathione and antioxidant
enzymes, and inhibit lactate dehydrogenase. Mice were treated as detailed in
Fig. 1 and described in Methods. Data are presented as mean   SD. Error bars
represent the SD. Co, control; LD, 2.5% Withania in the diet; HD, 5% Withania
in the diet. a (P   0.05) and b (P   0.01) indicate significant compared with
control.
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Figure 4. Roots of Withania inhibit B(a)P-induced forestomach papillo-
magenesis in mice. Mice were treated with B(a)P, and exposed to control and
test diets as described in Methods. Co, B(a)P   control diet; LD, B(a)P   2.5%
Withania in the diet; HD, B(a)P   5% Withania in the diet. (A) Initial and final
body weight, (B) Tumor incidence and (C) number of tumors (papillomas)/
animal. Data in (C) are presented as the mean   SD of 15–20 mice in each group.
d (P   0.01) indicates a significant change compared with control.mice fed with Withania diets compared with the control group,
indicating no apparent side effects or toxicity in the mice
(Fig. 4A). Further, forestomach tumors (Fig. 7A) were
processed for histopathological evaluation by hematoxylin and
eosin staining, showing that keratinized pearl was more preva-
lent in tumors of the control group of mice, representing an
advanced stage in tumor development of epithelial origin.
Together, these results showed that Withania root has prevent-
ive efficacy against carcinogen-induced forestomach papillo-
magenesis, and the lower dose used in the present study
showed slightly more preventive efficacy as compared with a
higher dose in this regard.
Withania Inhibits Carcinogen-induced Skin
Papillomagenesis in Mice
A representative picture of mice bearing skin papillomas in
each group is shown in Fig. 5. A single topical application of
50  g of DMBA/animal in acetone to the dorsal skin followed
by croton oil treatment induced tumors in 80% of the control
group of mice (12 out of 15) after 12 weeks of DMBA treat-
ment (Fig. 6A). The mean number of papillomas in the control
group was 3.17   2.4 papillomas/animal (Fig. 6B). The exper-
imental group fed with the lower dose (2.5%, w/w) Withania
diet (2 weeks before and 2 weeks after the DMBA treatment)
showed a 53% tumor incidence (Fig. 6A) and 1.1   1.6
papillomas/animal at the end of the experiment (Fig. 6B).
However, we observed no increase in tumor multiplicity after
eCAM 2005;2(1) 103
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Figure 5. Effect of roots of Withania on DMBA-induced papillomas in mouse
skin. Pictures were taken at the end of the experiment and are representative
for each group. Treatments were as indicated in the figure.
Figure 6. Roots of Withania inhibit DMBA-induced skin papillomagenesis
in mice. Mice were treated with DMBA and croton oil, and exposed 
to control and test diets. Co, DMBA   croton oil   control diet; LD,
DMBA   croton oil   2.5%  Withania in the diet; HD, DMBA   croton
oil   5%  Withania in the diet. (A) Tumor incidence and (B) tumor
number/group. Data in (B) are presented as the mean of 15 mice in each group.
d (P   0.01) indicate significant change compared with control.9 weeks of DMBA treatment. Mice fed with the higher dose
(5%, w/w) Withania diet showed only a 44% tumor incidence
(Fig. 6A) and 0.93   1.58 papillomas/animal (Fig. 6B). We
also observed that the high dose of Withania diet delayed
tumor appearance by 2 weeks (Fig. 6B). Further, skin tumors
(Fig. 7B) were processed for histopathological evaluation by
hematoxylin and eosin staining, in which tumors of the control
group of mice showed a relatively progressive stage of skin
tumor development as characterized by their cellular and
nuclear morphology as well as dermal invasiveness. These
results demonstrate the preventive efficacy of Withania root
against carcinogen-induced skin tumorigenesis in mice.
Discussion
Cancer chemoprevention involves pharmacological intervention
with synthetic or naturally occurring chemicals or substances
to prevent, inhibit or reverse the process of carcinogenesis or
to prevent the development of invasive cancer (27,28). In the
present study, the modulatory influence of roots of Withania
on xenobiotic drug metabolizing enzymes along with organ-
specific carcinogenesis was assessed. Our results suggest that
Withania root is basically a monofunctional inducer that
increases the activity of mainly phase II enzymes and has little
effect on phase I monofunctional oxygenases, which is also
supported by earlier studies (15). Our data show that Withania
root has little effect on the cyt P450 system. We further studied
the effect of Withania on phase II enzymes DTD and GST, as
well as other antioxidant enzymes SOD, CAT and reduced
glutathione (GSH) levels. They assist in conjugating eletrophilic
metabolites and carcinogens with endogenous ligands, thus
facilitating their removal from the cell (29). A number of
promising chemopreventive agents have been proved to be
potent inducers of GSH and GST, for example allylic sulfides,
oltipraz, N-acetyl cysteine, etc. (30). GST is a critical detoxifi-
cation enzyme that primarily functions in conjugating the cyt
P450 metabolites to endogenous ligands (GSH) favoring their
elimination from the body of the organisms (31). Induction of
DTD has been evaluated as a means of determining the
potency of many chemopreventive substances (32). Consistent
with these facts, we observed a significant induction in both
GST and DTD in Withania root-fed mice. In addition, we also
observed an increase in SOD and CAT activities, and increased
levels of GSH in Withania root-fed mice. These effects could
have a potential role in the detoxification and elimination of
potential carcinogens from the body, leading to the cancer
preventive efficacy of Withania roots as we observed in
carcinogen-induced forestomach and skin papillomagenesis.
However, more studies are needed to show the direct involve-
ment of the antioxidative potential of Withania roots in detox-
ification of carcinogens.
In the case of B(a)P-induced forestomach papillomagenesis,
tumor incidence as well as tumor burden were decreased in
Withania-fed mice. B(a)P is a polycyclic aromatic hydrocar-
bon and a potent inducer of forestomach carcinogenesis (33).
B(a)P is metabolized to its oxidized derivatives (epoxides,
phenols, diols, tetrols and quinones) by monooxygenases
and epoxide hydrolases. The moderately polar metabolites
are conjugated with sulfate, glucuronic acid and glutathione
by cytosolic enzymes to produce their water-soluble and
excretable forms. Since Withania moderately inhibited the
specific activities of cyt P450 and cyt b5, the conversion of
B(a)P to its epoxide would have been reduced, and at the same
time, an increase in the activity of phase II and antioxidant
enzymes could have facilitated the detoxification and
excretion of oxidized metabolites of B(a)P.
Withania roots were effective in reducing the tumor
incidence and tumor burden in DMBA-induced skin papillo-
magenesis. We observed a dose-dependent decrease in skin
tumor incidence; however, the dose-dependent inhibitory
effect of Withania roots on tumor burden was lost after
12 weeks of DMBA treatment. Reactive intermediates of skin
tumor initiators such as DMBA are mutagenic and bind cova-
lently to DNA of epidermal stem cells leading to transforma-
tion and irreversible alteration in the differentiation capacity of
these cells (27). TPA, one of the active principles of croton oil
that was used as a promoter in the present study, stimulates the
generation of superoxide radicals, hydrogen peroxide and lipid
peroxidation that may be involved in the process of tumor
promotion and can be interfered with by GST, DTD and CAT
(11,12,34). Since Withania significantly induces the specific
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Figure 7. Histopathology of tumor samples from forestomach and skin
papillomagenesis studies. Tissues samples were harvested at the end of each
experiment and processed for hematoxylin and eosin staining as mentioned in
Methods. A representative picture is shown for (A) forestomach tumor and
(B) skin tumor at 200  magnification in each case.activity of GST, DTD and CAT, we speculate that it can inter-
vene in the formation of active carcinogen as well as the
processes involved in tumor promotion. However, more stud-
ies are needed to confirm this. We also anticipate that an
immunomodulatory as well as an anti-inflammatory potential
of Withania roots might have contributed to its overall efficacy
against chemical carcinogenesis in forestomach and skin that
needs further investigation.
Withania is already popularly used as a home remedy for sev-
eral diseases such as arthritis, geriatric problems, fever, tuber-
culosis, asthma, etc., and is an official drug mentioned in the
Indian Pharmacopoeia. The findings of the present investiga-
tion support Withania root to be an effective cancer chemo-
preventive agent in a murine model system. Therefore, a
pre-clinical cancer chemoprevention study with Withania root
might help in generating valuable data to determine its useful-
ness in cancer chemoprevention in humans. Further studies are
needed to evaluate its pharmacokinetics and toxicity profile to
determine its clinical doses. No apparent toxicity of Withania
root (2.5 and 5%) in the diet in the present study is supportive
for advocating it as an effective and safe chemopreventive agent
in a mouse model; however, further studies are needed to assess
its effect with chronic administration. Isolation and identifica-
tion of bioactive components from Withania have attracted
many investigators in Asian countries. This suggests that
W.somnifera root should be explored for cancer chemopreven-
tive drug development, in addition to its existing utility as a
drug in the traditional medicine system of India, Ayurveda.
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